Bacterial ghosts as adjuvants in syngeneic tumour cell lysate-based anticancer vaccination in a murine lung carcinoma model

  • Authors:
    • Jan Aleksander Kraśko
    • Karolina Žilionytė
    • Adas Darinskas
    • Marius Strioga
    • Svetlana Rjabceva
    • Iosif Zalutsky
    • Marina Derevyanko
    • Vladimir Kulchitsky
    • Werner Lubitz
    • Pavol Kudela
    • Edita Miseikyte-Kaubriene
    • Olha Karaman
    • Hennadii Didenko
    • Hryhorii Potebnya
    • Vasyl Chekhun
    • Vita Pašukonienė
  • View Affiliations

  • Published online on: November 16, 2016     https://doi.org/10.3892/or.2016.5252
  • Pages: 171-178
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Instead of relying on external anticancer factors for treatment, immunotherapy utilizes the host's own immune system and directs it against given tumour antigens. This study demonstrated that it is possible to overcome the documented immunosuppressive properties of tumour cell lysate by supplementing it with appropriate adjuvant. Lewis lung carcinoma (LLC)‑challenged C57BL/6 mice were treated with LLC cryo‑lysate mixed with either bacterial ghosts (BGs) generated from E. coli Nissle 1917 or B. subtilis 70 kDa protein as adjuvants. Median and overall survival, the size of metastatic foci in lung tissue and levels of circulating CD8a+ T cells were evaluated and compared to the untreated control mice or mice treated with LLC lysate alone. After primary tumour removal, a course of three subcutaneous vaccinations with LLC lysate supplemented with BGs led to a significant increase in overall survival (80% after 84 days of follow‑up vs. 40% in untreated control mice), a significant increase in circulating CD8a+ T cells (16.57 vs. 12.6% in untreated control mice) and a significant decrease in metastasis foci area and incidence. LLC lysate supplemented with B. subtilis protein also improved the inspected parameters in the treated mice, when compared against the untreated control mice, but not to a significant degree. Therefore, whole cell lysate supplemented with BGs emerges as an immunostimulatory construct with potential clinical applications in cancer treatment.
View Figures
View References

Related Articles

Journal Cover

January-2017
Volume 37 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kraśko JA, Žilionytė K, Darinskas A, Strioga M, Rjabceva S, Zalutsky I, Derevyanko M, Kulchitsky V, Lubitz W, Kudela P, Kudela P, et al: Bacterial ghosts as adjuvants in syngeneic tumour cell lysate-based anticancer vaccination in a murine lung carcinoma model. Oncol Rep 37: 171-178, 2017
APA
Kraśko, J.A., Žilionytė, K., Darinskas, A., Strioga, M., Rjabceva, S., Zalutsky, I. ... Pašukonienė, V. (2017). Bacterial ghosts as adjuvants in syngeneic tumour cell lysate-based anticancer vaccination in a murine lung carcinoma model. Oncology Reports, 37, 171-178. https://doi.org/10.3892/or.2016.5252
MLA
Kraśko, J. A., Žilionytė, K., Darinskas, A., Strioga, M., Rjabceva, S., Zalutsky, I., Derevyanko, M., Kulchitsky, V., Lubitz, W., Kudela, P., Miseikyte-Kaubriene, E., Karaman, O., Didenko, H., Potebnya, H., Chekhun, V., Pašukonienė, V."Bacterial ghosts as adjuvants in syngeneic tumour cell lysate-based anticancer vaccination in a murine lung carcinoma model". Oncology Reports 37.1 (2017): 171-178.
Chicago
Kraśko, J. A., Žilionytė, K., Darinskas, A., Strioga, M., Rjabceva, S., Zalutsky, I., Derevyanko, M., Kulchitsky, V., Lubitz, W., Kudela, P., Miseikyte-Kaubriene, E., Karaman, O., Didenko, H., Potebnya, H., Chekhun, V., Pašukonienė, V."Bacterial ghosts as adjuvants in syngeneic tumour cell lysate-based anticancer vaccination in a murine lung carcinoma model". Oncology Reports 37, no. 1 (2017): 171-178. https://doi.org/10.3892/or.2016.5252